ACTU news & sentiment — ACTUATE THERAPEUTICS, INC.

JAN 6·Quiver QuantitativeMed

Actuate Therapeutics Reports Promising Initial Clinical Responses in Pediatric Cancers from Phase 1 Trial of Elraglusib

Actuate Therapeutics, Inc. announced promising initial clinical responses in pediatric cancers from its Phase 1 trial of elraglusib, noting two Complete Metabolic Responses in Ewing sarcoma and one Complete Response in neuroblastoma among 40 patients. The company plans to advance elraglusib's clinical development in 2026, especially for Ewing sarcoma, following its Rare Pediatric Designations from the FDA. Clinical responses and disease control were observed in 15 patients, with particular efficacy when elraglusib was combined with cyclophosphamide and topotecan.

SEP 22·GlobeNewswire

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc. ( NASDAQ: ACTU ) ( "Actuate" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the ...

SEP 10·Benzinga

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - Actuate Therapeutics ( NASDAQ:ACTU )

CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc.

$ACTU

Actuate Therapeutics Reports Promising Initial Clinical Responses in Pediatric Cancers from Phase 1 Trial of Elraglusib

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - Actuate Therapeutics ( NASDAQ:ACTU )

News on $ACTU